McKesson to Buy RX Savings in Deal Valued at $875 Million (2)

(Adds analyst comment from Truist starting in the fifth bullet.)

• Pharmaceuticals distributor McKesson Corp. entered a pact to buy Rx Savings Solutions for $600 million upfront and a maximum of $275 million contingent upon Rx’s financial performance through calendar year 2025.
• The deal to buy the pharma tech company is expected to close in the second half of fiscal 2023
• Evercore ISI analyst Elizabeth Anderson sees “minimal EPS dilution” to fiscal 2023
• “Today we start to see how MCK is envisioning its capital deployment,” she writes “Strategically, Rx Savings Solutions is a fast-growing pharma tech asset that should help to ...